Friday, 29 March 2024


USFDA grants EUA to Novavax COVID-19 vaccine for adolescents

22 August 2022 | News

Novavax' vaccine is the first protein-based COVID-19 vaccine authorised in the US

Image credit: shutterstock

Image credit: shutterstock

Novavax has announced that its COVID-19 caccine, Adjuvanted (NVX-CoV2373) has received expanded emergency use authorisation (EUA) from the US Food and Drug Administration (FDA) to provide a two-dose primary series for active immunisation to prevent COVID-19 in adolescents aged 12 through 17.

"Having more vaccine options for use in both adults and adolescents, like the Novavax COVID-19 Vaccine, Adjuvanted will hopefully help increase vaccination rates, particularly as we prepare for ongoing surges of COVID-19 with the start of fall and the back-to-school season," said Stanley C. Erck, President and Chief Executive Officer, Novavax. "We hope that our vaccine, developed using an innovative approach to recombinant protein vaccine technology, may have a special role in adolescent vaccination based on parents' and caregivers' familiarity with protein-based vaccines used in other disease areas."

The next step for the vaccine is a policy recommendation for use from the Centers for Disease Control and Prevention (CDC). Doses of the Novavax COVID-19 Vaccine, Adjuvanted are available for use in adolescents upon the CDC's recommendation.

In July 2022 the US FDA had granted EUA for a two-dose primary series in adults aged 18 and older, followed by a recommendation from the CDC Advisory Committee on Immunization Practices, and endorsement from the CDC.

 

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account